• 1
    Diamandis EP, Yousef GM, Luo LY, Magklara A & Obiezu CV (2000) The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11, 5460.
  • 2
    Yousef GM & Diamandis EP (2001) The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22, 184204.
  • 3
    Borgoño CA, Michael IP & Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2, 257280.
  • 4
    Clements JA, Willemsen NM, Myers SA & Dong Y (2004) The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Laboratory Sci 41, 265312.
  • 5
    Tremblay RR, Deperthes D, Tetu B & Dube JY (1997) Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 150, 455459.
  • 6
    Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE & Lilja H (2000) Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163, 311316.
  • 7
    Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland E, Huland H & Lilja H (2003) Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 170, 22692273.
  • 8
    Anisowicz A, Sotiropoulou G, Stenman G, Mok SC & Sager R (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2, 624636.
  • 9
    Dhar S, Bhargava R, Yunes M, Li B, Goyal J, Naber SP, Waser DE & Band V (2001) Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res 7, 33933398.
  • 10
    Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R & Diamandis EP (2002) Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Clin Cancer Res 86, 14571464.
  • 11
    Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J et al. (2003) Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 63, 39583965.
  • 12
    Luo LY, Yousef G & Diamandis EP (2003) Human tissue kallikreins and testicular cancer. APMIS 111, 225233.
  • 13
    Yousef GM, Magklara A, Chang A, Jung K, Katsaros D & Diamandis EP (2001) Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61, 34253431.
  • 14
    Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK & Clements JA (2001) Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73, 117122.
  • 15
    Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D & Diamandis EP (2003) Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 63, 90329041.
  • 16
    Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP & Katsaros D (2003) Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 119, 346355.
  • 17
    Yousef GM, Borgono CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P & Diamandis EP (2002) Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer 87, 12871293.
  • 18
    Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME & Diamandis EP (2003) Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56, 287292.
  • 19
    Felber LM, Borgoño CA, Cloutier SM, Kündig C, Kishi T, Chagas JR, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP et al. (2004) Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem 386, 291298.
  • 20
    Cloutier SM, Kündig C, Felber LM, Fattah OM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ & Deperthes D (2004) Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur J Biochem 271, 607613.
  • 21
    Borgono CA & Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4, 876890.
  • 22
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K & Alfthan O (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51, 222226.
  • 23
    Espana F, Sanchez-Cuenca J, Vera CD, Estelles A & Gilabert J (1993) A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 122, 711719.
  • 24
    Deperthes D, Chapdelaine P, Tremblay RR, Brunet C, Berton J, Hebert J, Lazure C & Dube JY (1995) Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1245, 311316.
  • 25
    Deperthes D, Frenette G, Brillard-Bourdet M, Bourgeois L, Gauthier F, Tremblay RR & Dube JY (1996) Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 17, 659665.
  • 26
    Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD & Wolfert RL (1998) Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl 19, 407411.
  • 27
    Zhou GX, Chao L & Chao J (1992) Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. Biochem J 339, 473479.
  • 28
    Hutchinson S, Luo LY, Yousef GM, Soosaipillai A & Diamandis EP (2003) Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha (1)-antichymotrypsin. Clin Chem 49, 746751.
  • 29
    Baumann U, Huber R, Bode W, Grosse D, Lesjak M & Laurell CB (1991) Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7 Å resolution and its comparison with other serpins. J Mol Biol 218, 595606.
  • 30
    Wei A, Rubin H, Cooperman BS & Christianson DW (1994) Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nat Struct Biol 1, 251258.
  • 31
    Stratikos E & Gettins PG (1998) Mapping the serpin-proteinase complex using single cysteine variants of alpha1-proteinase inhibitor Pittsburgh. J Biol Chem 273, 1558215589.
  • 32
    Wilczynska M, Fa M, Karolin J, Ohlsson PI, Johansson LB & Ny T (1997) Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol 4, 354357.
  • 33
    Luke C, Schick C, Tsu C, Whisstock JC, Irving JA, Bromme D, Juliano L, Shi GP, Chapman HA & Silverman GA (2000) Simple modifications of the serpin reactive site loop convert SCCA2 into a cysteine proteinase inhibitor: a critical role for the P3′ proline in facilitating RSL cleavage. Biochemistry 39, 70817091.
  • 34
    Plotnick MI, Samakur M, Wang ZM, Liu X, Rubin H, Schechter NM & Selwood T (2002) Heterogeneity in serpin-protease complexes as demonstrated by differences in the mechanism of complex breakdown. Biochemistry 41, 334342.
  • 35
    Djie MZ, Le Bonniec BF, Hopkins PC, Hipler K & Stone SR (1996) Role of the P2 residue in determining the specificity of serpins. Biochemistry 35, 1146111469.
  • 36
    Chen VC, Chao L & Chao J (2000) Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. Biol Chem 275, 3845738466.
  • 37
    Dufour EK, Denault JB, Bissonnette L, Hopkins PC, Lavigne P & Leduc R (2001) The contribution of arginine residues within the P6–P1 region of alpha 1-antitrypsin to its reaction with furin. J Biol Chem 276, 3897138979.
  • 38
    McRae B, Nakajima K, Travis J & Powers JC (1980) Studies on reactivity of human leukocyte elastase, cathepsin G, and porcine pancreatic elastase toward peptides including sequences related to the reactive site of alpha 1-protease inhibitor (alpha 1-antitrypsin). Biochemistry 19, 39733978.
  • 39
    Ibarra CA, Blouse GE, Christian TD & Shore JD (2004) The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 279, 36433650.
  • 40
    Pizzo SV, Mast AE, Feldman SR & Salvesen G (1988) In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta 967, 158162.
  • 41
    Mast AE, Enghild JJ, Pizzo SV & Salvesen G (1991) Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 30, 17231730.
  • 42
    Enghild JJ, Valnickova Z, Thogersen IB & Pizzo SV (1994) Complexes between serpins and inactive proteinases are not thermodynamically stable but are recognized by serpin receptors. J Biol Chem 269, 2015920166.
  • 43
    Kapadia C, Chang A, Sotiropoulo G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DH & Diamandis EP (2003) Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 49, 7786.
  • 44
    Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W et al. (1997) Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 272, 2513525142.
  • 45
    Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C & Diamandis EP (2003) Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin Chem 49, 8796.
  • 46
    Shimizu C, Yoshida S, Shibata M, Kato K, Momota Y, Matsumoto K, Shiosaka T, Midorikawa R, Kamachi T, Kawabe A et al. (1998) Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J Biol Chem 273, 1118911196.
  • 47
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ & Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150, 7685.
  • 48
    Morrison JF & Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61, 201301.